Intervention/Treatment: The trial tests Itepekimab, administered subcutaneously in high and low doses, alongside Mometasone furoate nasal spray. The purpose is to improve symptoms in patients with ...

Research and development expenses were $37.9 million for the quarter ended June 30, 2025, compared to $14.1 million for the same period in 2024. The increase of $23.8 million was primarily driven by ...

The FDA has extended the review period for elinzanetant for the treatment of moderate to severe vasomotor symptoms due to menopause.

Therapeutic blockade of the TSLP ligand is a well-validated approach that has demonstrated clinically meaningful efficacy in asthma, chronic obstructive pulmonary disease (COPD), and chronic ...

CRSwNP associated with late onset asthma in a patient with blood eosinophilia, undergoing chronic OCS treatment should be considered an important red flag for a possible EGPA (40). However, beyond ...

The treatment is intended to improve symptoms in patients with CRSwNP. Study Design: The study is interventional, with participants randomly assigned to different treatment groups.